Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05505357
Other study ID # KBCSG-24
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 22, 2022
Est. completion date June 2031

Study information

Verified date November 2023
Source Seoul National University Hospital
Contact Han-Byoel Lee
Phone +82-2-2072-3447
Email hblee80@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, multicenter, single-arm non-inferiority trial to demonstrate that breast cancer patients who are predicted to have a pathologic complete response on MRI and vacuum-assisted biopsy after neoadjuvant systemic therapy, and are omitted breast surgery have a non-inferior 5-year disease-free survival compared to those who had received breast surgery.


Description:

[Background & Rationale for Study] Optimization (rather than de-escalation) of surgery for breast cancer is essential for our patients, and thus it is an important topic discussed actively in all major conferences regarding breast cancer and oncology. A previous study showed that lesion-to-background parenchymal signal enhancement ratio (L-to-B SER) ≤1.6 and/or size ≤ 0.2cm on breast MRI can distinguish pathological complete response (pCR) from minimal residual cancer following neoadjuvant systemic therapy (NST). In a separate prospective study, 40 patients with near pCR (either tumor size ≤ 0.5 cm or L-to-B SER ≤ 1.6 on MRI) were enrolled and evaluated for the accuracy of US-guided biopsy aided by MRI in predicting pCR in the breast after NST. US-guided multiple core needle biopsy (CNB) or VAB of the tumor bed, followed by standard surgical excision, was performed. Matched biopsy and surgical specimens were compared to assess pCR. In result, obtaining at least 5 biopsy cores based on tumor size ≤ 0.5 cm and an L-to-B SER of ≤ 1.6 on MRI resulted in 100% NPV and accuracy. No differences in accuracy were noted between CNB and VAB (90% vs. 90%). It was demonstrated that patients who meet these stringent criteria on MRI may forego surgery for breast cancer. Also, a pooled analysis of data from The Royal Marsden, MD Anderson Cancer Center, and Seoul National University Hospital showed that a VAB obtaining at least 6 cores for a lesion ≤2cm on imaging after NST can accurately predict pCR at a FNR of 3.2%. For patients who would not benefit from surgery, it is unnecessary in terms of both personal and national medical expenses. Therefore, in order to establish the rationale for whether surgery could be omitted for patients with predicted pCR, it is necessary to demonstrate that the survival rate of patients who skipped breast surgery after confirming no residual cancer on VAB is non-inferior than that of patients who underwent breast surgery. [Study Objectives] To show non-inferiority in terms of disease-free survival (DFS) of omission of breast surgery for breast cancer patients who show no residual tumor on VAB after NST. [Study design] Prospective, multicenter, single-arm, non-inferiority trial


Recruitment information / eligibility

Status Recruiting
Enrollment 533
Est. completion date June 2031
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria: - Sex: female - Age: 20 years and older - Patients with no clinical/radiologic distant metastasis - Tumor type: Invasive ductal carcinoma - Tumor subtype: HER2 positive(including luminal B type, triple negative - Extent of disease: initial tumor size = 5cm, cN0-2 - Patients with measurable tumor size - Patients who are expected to achieve pCR after neoadjuvant chemotherapy (MRI size = 1.0 cm AND L-to-B SER = 1.6) - Patients with clip inserted to the primary tumor site before or during neoadjuvant chemotherapy - Patients with informed consent who are competent to make a voluntary decision Exclusion Criteria: - Multifocal lesion (=2) - Extent of residual microcalcification after neoadjuvant chemotherapy > 2cm - Bilateral breast cancer or inflammatory breast cancer - Contraindication to radiotherapy - History of previous contralateral breast cancer - Breast cancer patients with distant metastasis - Allergic history to MRI contrast - Male breast cancer - Patients incapable of giving informed consent owing to poor general conditions - Patients with BRCA mutation - Patients willing to receive breast surgery - Patients with a history of cancer diagnosis within 5 years (However, skin cancer other than melanoma and breast carcinoma in situ other than ductal carcinoma in situ can be registered even if 5 years have not passed since the diagnosis)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Breast surgery omission
For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (2)

Lead Sponsor Collaborator
Seoul National University Hospital Ministry of Health & Welfare, Korea

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (3)

Kim SY, Cho N, Shin SU, Lee HB, Han W, Park IA, Kwon BR, Kim SY, Lee SH, Chang JM, Moon WK. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour. Eur Radiol. 2018 Jul;28(7):2986-2995. doi: 10.1007/s00330-017-5251-8. Epub 2018 Jan 29. — View Citation

Lee HB, Han W, Kim SY, Cho N, Kim KE, Park JH, Ju YW, Lee ES, Lim SJ, Kim JH, Ryu HS, Lee DW, Kim M, Kim TY, Lee KH, Shin SU, Lee SH, Chang JM, Moon HG, Im SA, Moon WK, Park IA, Noh DY. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. Breast Cancer Res Treat. 2020 Jul;182(1):97-105. doi: 10.1007/s10549-020-05678-3. Epub 2020 May 16. — View Citation

Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg. 2020 Dec 1;155(12):e204103. doi: 10.1001/jamasurg.2020.4103. Epub 2020 Dec 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-Free Survival Proportion of patients with no disease recurrence (including loco-regional recurrence, distant metastasis, and contralateral breast cancer) or death. 5 years after axillary surgery or VAB (in case of axillary surgery omission)
Secondary Ipsilateral Breast Tumor Recurrence-Free Survival Ipsilateral Breast Tumor Recurrence-Free Survival Proportion of patients with no disease recurrence in the ipsilateral breast or death 5 years after axillary surgery or VAB (in case of axillary surgery omission)
Secondary Overall Survival Proportion of patients with no death. 5 years after axillary surgery or VAB (in case of axillary surgery omission)
Secondary Invasive Disease-Free Survival Invasive Disease-Free Survival Proportion of patients with no invasive disease recurrence (including loco-regional recurrence, distant metastasis, and contralateral breast cancer) or death. 5 years after axillary surgery or VAB (in case of axillary surgery omission)
Secondary QoL, symptoms, and medical cost Analysis of QoL survey (BREAST-Q), procedure-related symptoms, and medical cost 1 year after axillary surgery or VAB (in case of axillary surgery omission)
Secondary Rate of residual axillary lymph node metastasis on axillary surgery Proportion of patients with metastatic lymph nodes among those with pCR on VAB Upon axillary surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03664895 - Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) Phase 3
Completed NCT03669705 - No Axillary Surgery for Early Breast Cancer.
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Recruiting NCT05877859 - Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Active, not recruiting NCT04398914 - Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Recruiting NCT05351424 - AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc N/A
Active, not recruiting NCT03627988 - Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy. Phase 2
Completed NCT05300412 - The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer
Recruiting NCT04999917 - Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer N/A
Recruiting NCT05910398 - Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer Phase 3
Completed NCT05019989 - Trial of Diet, Physical Activity and Breast Cancer Recurrences: the DIANA-5 Study N/A
Recruiting NCT06144944 - Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer Phase 3
Recruiting NCT04891068 - BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer Phase 2
Recruiting NCT05939310 - Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study N/A
Recruiting NCT06401304 - Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Completed NCT05463276 - The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
Completed NCT04729647 - Immature Granulocyte Count and Delta Neutrophil Index Factors for Axillary Metastasis of Breast Cancer N/A
Active, not recruiting NCT06234488 - Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
Recruiting NCT00437879 - Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.